Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
Altimmune, Inc. (Nasdaq: ALT) will report its Q3 2022 financial results on November 10, 2022, followed by a management conference call at 8:30 am ET. The discussion will focus on financial performance and business updates. Live streaming of the call will be available on the company's Investor Relations website. Altimmune specializes in peptide-based therapeutics for obesity and liver diseases, with its lead candidate being pemvidutide, aimed at treating obesity and non-alcoholic steatohepatitis (NASH).
- Altimmune's lead product pemvidutide aims to address obesity and NASH, indicating potential for significant market demand.
- The scheduled financial results and business update may enhance investor confidence and provide transparency.
- None.
GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on November 10 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to twelve months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
FAQ
When will Altimmune report its Q3 2022 financial results?
What is the focus of Altimmune's upcoming conference call?
What product is Altimmune developing for obesity treatment?
What therapeutic area does Altimmune specialize in?
